METHODS OF REDUCING SMALL, DENSE LDL PARTICLES
The present invention provides methods for increasing LDL particle size.
1 . A method of decreasing the amount of small, dense LDL particles in a human having LDL particle size pattern I or B, the method comprising,
administering a therapeutically-effective amount of a compound of Formula I or a salt, prodrug or isomer thereof to the human wherein the LDL particle size pattern is changed after administration:
from pattern Ito pattern A; or
from pattern B to pattern I or A.
2 . The method of claim 1 , wherein the human has a lower level of LDL-III particles after the administrating step compared to prior to the administering step.
3 . The method of claim 1 , wherein the human has a lower level of LDL-IV particles after the administrating step compared to prior to the administering step.
4 . The method of claim 1 , wherein the compound is
or a salt, prodrug or isomer thereof.
5 . The method of claim 1 , wherein said compound is
or a salt or prodrug thereof.
6 . The method of claim 1 , wherein the human has an LDL particle size pattern A after 10 days after the administering step.
7 . The method of claim 1 , further comprising measuring the LDL particle diameter of the human prior to the administering step.
8 . The method of claim 1 , further comprising measuring the LDL particle diameter of the human after the administering step.
9 . The method of claim 1 , wherein the human has an LDL particle size pattern B prior to the administering step.
10 . The method of claim 1 , wherein Apolipoprotein B-100 blood levels are reduced at least 10% after 10 days of the administering step.
11 . The method of claim 1 , wherein absorption of cholesterol is reduced by least 5% after 10 days of the administering step.
12 . The method of claim 1 , wherein cholesterol synthesis is reduced at least 5% after 10 days of the administering step.
13 . A method of reducing triglycerides and LDL blood levels in a human having LDL particle size pattern I or B, the method comprising
administering a therapeutically-effective amount of a compound of Formula I or a salt, prodrug or isomer thereof to the human wherein the LDL particle size pattern is changed after administration:
from pattern Ito pattern A; or
from pattern B to pattern I or A.
14 . The method of claim 13 , wherein the compound is
or a salt, prodrug or isomer thereof.
15 . The method of claim 13 , wherein said compound is
or a salt or prodrug thereof.
16 . The method of claims 13 , further comprising administrating a statin to the human.
17 . The method of claim 16 , wherein the statin is Atorvastatin.
18 . A method of identifying a candidate individual for treatment with a compound of Formula I or a salt, prodrug or isomer thereof, the method comprising,
measuring the LDL peak particle diameter of an individual; and
administering the compound to the individual if the individual had a pattern I or B LDL particle size pattern.
19 . The method of claim 18 , wherein the individual has a pattern I LDL particle size pattern and the compound is administered to the individual after the measuring step.
20 . The method of claim 18 , wherein the individual has a pattern B LDL particle size pattern and the compound is administered to the individual after the measuring step.